HC Wainwright Lifts Earnings Estimates for Opus Genetics

Opus Genetics, Inc. (NASDAQ:IRD) – Equities researchers at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for shares of Opus Genetics in a report issued on Wednesday, May 13th. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.15) per share for the quarter, up from their prior forecast of ($0.16). The consensus estimate for Opus Genetics’ current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Opus Genetics’ Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($1.18) EPS and FY2027 earnings at ($0.46) EPS.

Opus Genetics (NASDAQ:IRD) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.59). Opus Genetics had a negative net margin of 892.36% and a negative return on equity of 709.20%. The firm had revenue of $2.16 million for the quarter, compared to analyst estimates of $2.93 million.

IRD has been the topic of several other reports. Wall Street Zen upgraded Opus Genetics from a “sell” rating to a “hold” rating in a research note on Sunday, March 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a research note on Tuesday, April 21st. Citizens Jmp reduced their price objective on Opus Genetics from $12.00 to $11.00 and set a “market outperform” rating on the stock in a research note on Wednesday. Zacks Research cut Opus Genetics from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Finally, Citigroup initiated coverage on Opus Genetics in a research note on Tuesday, April 28th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.20.

Opus Genetics Price Performance

Shares of IRD opened at $4.97 on Friday. The business’s fifty day moving average price is $4.99 and its 200 day moving average price is $3.33. Opus Genetics has a 12-month low of $0.90 and a 12-month high of $5.81. The stock has a market capitalization of $404.56 million, a PE ratio of -3.74 and a beta of 0.62.

Insider Buying and Selling

In other Opus Genetics news, CFO Robert E. Gagnon sold 7,842 shares of the stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $5.18, for a total value of $40,621.56. Following the sale, the chief financial officer directly owned 592,158 shares of the company’s stock, valued at $3,067,378.44. This trade represents a 1.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Ashwath Jayagopal sold 7,542 shares of the stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $5.19, for a total value of $39,142.98. Following the completion of the sale, the insider directly owned 509,233 shares in the company, valued at $2,642,919.27. This represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 73,395 shares of company stock valued at $382,278 over the last three months. Corporate insiders own 11.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Nantahala Capital Management LLC increased its holdings in shares of Opus Genetics by 42.9% during the fourth quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock valued at $9,610,000 after purchasing an additional 1,435,407 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Opus Genetics during the fourth quarter valued at $5,463,000. Millennium Management LLC acquired a new position in shares of Opus Genetics during the fourth quarter valued at $4,025,000. Mink Brook Asset Management LLC increased its holdings in shares of Opus Genetics by 34.5% during the fourth quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock valued at $3,348,000 after purchasing an additional 427,684 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Opus Genetics by 35.3% during the third quarter. Vanguard Group Inc. now owns 1,342,025 shares of the company’s stock valued at $2,214,000 after purchasing an additional 349,825 shares during the period. 14.97% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: HC Wainwright raised its Q2, Q3, Q4 2026, and FY2027 EPS estimates for Opus Genetics, suggesting slightly better expectations for the company’s later-period losses.
• Positive Sentiment: Citizens JMP kept a market outperform rating and only trimmed its price target to $11 from $12, still implying substantial upside from the current share price.
• Neutral Sentiment: Recent coverage from multiple analysts indicates ongoing interest in the stock, but the commentary is mixed rather than uniformly bullish. Article Title
• Neutral Sentiment: The company was also noted as being projected to report earnings, keeping attention on upcoming results and guidance. Article Title
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS estimate significantly, highlighting expectations for a larger loss this year.
• Negative Sentiment: Lifesci Capital cut Q2, Q3, Q4 2026 and FY2026 EPS estimates, reinforcing concern that profitability remains out of reach in the near term.
• Negative Sentiment: Zacks Research downgraded Opus Genetics from hold to strong sell, adding pressure on the stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.